<article article-type="case-report" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ACG Case Rep J</journal-id><journal-id journal-id-type="iso-abbrev">ACG Case Rep J</journal-id><journal-id journal-id-type="pmc-domain-id">2725</journal-id><journal-id journal-id-type="pmc-domain">acgcasereps</journal-id><journal-id journal-id-type="publisher-id">AC9</journal-id><journal-title-group><journal-title>ACG Case Reports Journal</journal-title></journal-title-group><issn pub-type="epub">2326-3253</issn><publisher><publisher-name>American College of Gastroenterology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12900214</article-id><article-id pub-id-type="pmcid-ver">PMC12900214.1</article-id><article-id pub-id-type="pmcaid">12900214</article-id><article-id pub-id-type="pmcaiid">12900214</article-id><article-id pub-id-type="pmid">41696669</article-id><article-id pub-id-type="doi">10.14309/crj.0000000000002008</article-id><article-id pub-id-type="publisher-id">ACGCR-25-0889</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="Version of Record" vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Liver</subject></subj-group></article-categories><title-group><article-title>Treatment of Steroid-Refractory Immune Checkpoint-Related Hepatitis With Ruxolitinib</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Nguyen</surname><given-names initials="VV">Vivian V.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wells</surname><given-names initials="M">Malcolm</given-names></name><degrees>MD</degrees><email>mwells1@ualberta.ca</email><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moctezuma-Velazquez</surname><given-names initials="C">Carlos</given-names></name><degrees>MD, MSc</degrees><email>moctezum@ualberta.ca</email><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Anaka</surname><given-names initials="MR">Matthew R.</given-names></name><degrees>MD</degrees><email>manaka@ualberta.ca</email><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Walker</surname><given-names initials="J">John</given-names></name><degrees>MD</degrees><email>jwwalker@ualberta.ca</email><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lytvyak</surname><given-names initials="E">Ellina</given-names></name><degrees>MD, PhD</degrees><email>lytvyak@ualberta.ca</email><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tandon</surname><given-names initials="P">Puneeta</given-names></name><degrees>MD, MSc</degrees><email>ptandon@ualberta.ca</email><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bhanji</surname><given-names initials="RA">Rahima A.</given-names></name><degrees>MD, MSc</degrees><email>rbhanji@ualberta.ca</email><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Montano-Loza</surname><given-names initials="AJ">Aldo J.</given-names></name><degrees>MD, MSc, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label>Division of Gastroenterology and Hepatology, University of Alberta, Edmonton, Alberta, <country>Canada</country></aff><aff id="aff2"><label>2</label>Department of Oncology, University of Alberta, Edmonton, Alberta, <country>Canada</country></aff><aff id="aff3"><label>3</label>Department of Preventive Medicine, University of Alberta, Edmonton, <country>Canada</country></aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence:</bold> Vivian V. Nguyen, MD, FRCPC (<email>vvn@ualberta.ca</email>) Aldo J. Montano-Loza, MD, MSc, PhD, FAASLD, FACG (<email>montanol@ualberta.ca</email>).</corresp></author-notes><pub-date pub-type="collection"><month>2</month><year>2026</year></pub-date><pub-date pub-type="epub"><day>12</day><month>2</month><year>2026</year></pub-date><volume>13</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">506896</issue-id><elocation-id>e02008</elocation-id><history><date date-type="received"><day>28</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>1</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>02</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>13</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-16 15:25:13.347"><day>16</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© 2026 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref content-type="ccbyncndlicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="ac9-13-e02008.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><self-uri xlink:href="ac9-13-e02008.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract><title>ABSTRACT</title><p>The incidence of immune-related hepatitis (IRH) is rising due to increasing use of immune checkpoint inhibitors for the treatment of several malignancies. While most cases respond to corticosteroid therapy, some patients require additional immunosuppressive agents, for which evidence to guide management is still evolving. We present the first documented case of ruxolitinib use as a tertiary agent for IRH following failure of corticosteroids and tocilizumab, suggesting a potential role for Janus kinase inhibitors as a rescue therapy for severe IRH.</p></abstract><kwd-group><title>KEYWORDS:</title><kwd>immune-related hepatitis</kwd><kwd>steroid-refractory hepatitis</kwd><kwd>immune checkpoint inhibitors</kwd><kwd>ruxolitinib</kwd><kwd>tocilizumab</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>INTRODUCTION</title><p>Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but can lead to immune-related adverse events due to anti-tumor activity and immune activation. Immune-related hepatitis (IRH) occurs in up to 25% of patients on ICI therapy.<sup><xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R3">3</xref></sup> A clinically important subset of patients fail to respond to corticosteroid therapy and require secondary or tertiary immunosuppressive agents.<sup><xref ref-type="bibr" rid="R4">4</xref></sup> Current guideline recommendations for optimal agent selection and timing of escalation remain largely based on observational data and expert consensus. We report a case of severe steroid-refractory hepatitis and the use of ruxolitinib as a rescue agent after failure of corticosteroids and tocilizumab.</p></sec><sec id="s2"><title>CASE REPORT</title><p>A 56-year-old man with biopsy-confirmed melanoma underwent complete surgical excision and adjuvant therapy with dabrafenib and trametinib. After 10 months of adjuvant therapy, surveillance imaging showed recurrent metastatic disease to the lungs. Dabrafenib and trametinib were discontinued and he was started on combination immunotherapy with nivolumab and ipilimumab 4 weeks later. He did not have prior chronic liver diseases, and his liver enzymes were normal before any treatment initiation. He received a cycle every 3 weeks and completed 4 cycles of combination therapy. Liver enzyme trend is shown in Figure <xref ref-type="fig" rid="F1">1</xref>. Three weeks following the fourth cycle, he developed significant elevations in liver enzymes with alanine aminotransferase (ALT) of 2989 U/L, aspartate aminotransferase (AST) of 2612 U/L, alkaline phosphatase (ALP) of 421, and bilirubin of 81 umol/L. Other causes of acute liver injury were excluded including negative viral serologies, negative autoimmune work-up, a normal Doppler ultrasound, and a medication review to exclude other causes of drug-induced liver injury. Liver biopsy was deferred given the low suspicion for an alternative diagnosis. Ultimately, grade 4 IRH was diagnosed. His immunotherapy was held, and prednisone 60 mg (0.75 mg/kg) was initiated. Although guideline-recommended dosing was 1–2 mg/kg/day, a lower dose was used due to patient frailty and several metabolic comorbidities. After 5 days of prednisone, his liver enzymes worsened with ALT of 3399 U/L, AST 1828 U/L, ALP 400 U/L, and bilirubin of 154 U/L. His prednisone was appropriately increased to 90 mg daily. He was admitted to the hospital and started on intravenous (IV) methylprednisolone 100 mg twice daily, consistent with the current guideline recommended dosing of 2 mg/kg/day for severe IRH. Although higher pulse steroid regimens exist for other disease contexts, they are not established in the guidelines for IRH.<sup><xref ref-type="bibr" rid="R5">5</xref></sup> Despite 6 days of methylprednisolone, there was no biochemical improvement. On his seventh day, he received 1 dose of tocilizumab IV 4 mg/kg. After another 3 days without improvement, methylprednisolone was increased to 500 mg IV daily in an attempt to salvage the case and ruxolitinib 5 mg oral twice daily was initiated. Of note, varicella-zoster vaccination was up-to-date, and he was simultaneously placed on trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia prophylaxis. His liver enzymes improved within 24 hours. Ruxolitinib was continued for 30 days. His methylprednisolone was transitioned to oral steroids over the next 3 days and tapered off completely over 3 months. Liver enzymes normalized 14 weeks after diagnosis. Immunotherapy was not restarted.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Timeline for a novel case of steroid-refractory immune-related hepatitis treated with ruxolitinib. A: Last dose of immunotherapy given, B: Prednisone 60 mg (0.75 mg/kg) daily initiated, C: Prednisone 90 mg (1 mg/kg) daily initiated, D: Admitted to hospital. Methylprednisolone 100 mg twice daily initiated (2 mg/kg/day), E: Tocilizumab 4 mg/kg × 1 dose, F: Methylprednisolone increased to 500 mg once daily and ruxolitinib 5 mg twice daily started. ALT, alanine aminotransferase; AST, aspartate aminotransferase.</p></caption><graphic orientation="portrait" position="float" xlink:href="ac9-13-e02008-g001.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>At the same center, 4 other patients were diagnosed with severe steroid refractory hepatitis and were managed successfully with mycophenolate mofetil (MMF) (Table <xref ref-type="table" rid="T1">1</xref>). All patients achieved normalization of their liver enzymes after a median follow-up period of 10 weeks.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Four additional cases of severe immune checkpoint-related hepatitis</p></caption><table frame="hsides" rules="groups"><thead><tr><td colspan="1" rowspan="1">Case</td><td colspan="1" rowspan="1">Case 1</td><td colspan="1" rowspan="1">Case 2</td><td colspan="1" rowspan="1">Case 3</td><td colspan="1" rowspan="1">Case 4</td></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">72</td><td colspan="1" rowspan="1">71</td><td colspan="1" rowspan="1">69</td></tr><tr><td colspan="1" rowspan="1">Sex</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">M</td></tr><tr><td colspan="1" rowspan="1">Malignancy</td><td colspan="1" rowspan="1">Colorectal cancer</td><td colspan="1" rowspan="1">Melanoma</td><td colspan="1" rowspan="1">Melanoma</td><td colspan="1" rowspan="1">NSCLC</td></tr><tr><td colspan="1" rowspan="1">ICI</td><td colspan="1" rowspan="1">Pembrolizumab</td><td colspan="1" rowspan="1">Nivolumab</td><td colspan="1" rowspan="1">Ipilimumab and nivolumab</td><td colspan="1" rowspan="1">Pembrolizumab</td></tr><tr><td colspan="1" rowspan="1">Cycles of ICI<sup><xref ref-type="table-fn" rid="tblfn1">a</xref></sup></td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1">CTCAE grade</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">Peak ALT/AST (U/L)</td><td colspan="1" rowspan="1">263/274</td><td colspan="1" rowspan="1">697/356</td><td colspan="1" rowspan="1">2,500/1,337</td><td colspan="1" rowspan="1">305/145</td></tr><tr><td colspan="1" rowspan="1">Steroid therapy</td><td colspan="1" rowspan="1">Prednisone 2 mg/kg, taper</td><td colspan="1" rowspan="1">Prednisone 1 mg/kg, taper</td><td colspan="1" rowspan="1">Methylprednisolone 1 mg/kg, taper</td><td colspan="1" rowspan="1">Prednisone 1.5 mg/kg, taper</td></tr><tr><td colspan="1" rowspan="1">Time to secondary agent (weeks)<sup><xref ref-type="table-fn" rid="tblfn2">b</xref></sup></td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1">Secondary agent</td><td colspan="1" rowspan="1">MMF 500 mg bid</td><td colspan="1" rowspan="1">MMF 500 mg bid × 4 weeks, then MMF 1000 mg bid</td><td colspan="1" rowspan="1">MMF 500 mg bid × 1 week, then MMF 1000 mg bid</td><td colspan="1" rowspan="1">MMF 500 mg bid</td></tr><tr><td colspan="1" rowspan="1">Outcome</td><td colspan="1" rowspan="1">Normalization of liver enzymes 8 weeks after MMF</td><td colspan="1" rowspan="1">Normalization of liver enzymes 20 weeks after MMF</td><td colspan="1" rowspan="1">Normalization of liver enzymes 6 weeks after MMF</td><td colspan="1" rowspan="1">Normalization of liver enzymes 12 weeks after MMF</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>ALT, alanine aminotransaminase; AST, aspartate aminotransaminase; bid, twice daily dosing; CTCAE, common terminology criteria for adverse events; ICI, immune checkpoint inhibitor; MMF, mycophenolate mofetil; NSCLC, Non-small cell lung cancer.</p></fn><fn fn-type="other" id="tblfn1"><label>a</label><p>Cycles of ICI received before treatment was held.</p></fn><fn fn-type="other" id="tblfn2"><label>b</label><p>Time (weeks) on systemic steroids before a secondary agent was initiated.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3" sec-type="discussion"><title>DISCUSSION</title><p>Risk factors of IRH include pre-existing liver disease, hepatocellular cancer, combination immunotherapy, and higher ICI dose.<sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R6">6</xref></sup> The Common Terminology Criteria for Adverse Events (CTCAE) define severity based on the degree of liver enzyme elevation.<sup><xref ref-type="bibr" rid="R7">7</xref></sup> Severe hepatitis is defined as grade 3 (ALT/AST ≥ 5 to 20 times the upper limit of normal (ULN) and/or total bilirubin ≥ 3 to 10 times the ULN) or grade 4 hepatitis (ALT/AST ≥ 20 times the ULN and/or total bilirubin ≥ 10 times the ULN). In mild to moderate cases (grade 1 and 2), IRH typically resolves within 4 to 6 weeks of ICI withdrawal. In severe cases (grades 3 and 4), guidelines recommend: (i) discontinuation of ICI, (ii) gastroenterology or hepatology consultation, and (iii) initiation of corticosteroids at a dose of 1–2 mg/kg/day prednisone equivalent.<sup><xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R8">8</xref></sup> While imaging and liver biopsy are important to rule out other causes of liver injury, it is not necessary for diagnosis of IRH or treatment initiation.<sup><xref ref-type="bibr" rid="R4">4</xref></sup></p><p>Approximately 30% of patients with IRH are corticosteroid nonresponders and require additional immunosuppression.<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R8">8</xref></sup> These patients are classified as either steroid-dependent (initial improvement of liver enzymes with subsequent worsening following steroid taper) or steroid-refractory (failure of liver enzymes to improve after at least 48–72 hours of therapy).<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9">9</xref></sup></p><p>Current guidelines commonly recommend MMF, azathioprine, and tacrolimus as secondary agents.<sup><xref ref-type="bibr" rid="R4">4</xref></sup> Other recommendations include cyclosporine and anti-thymocyte globulin, the latter reserved for fulminant hepatitis.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> While MMF is the most commonly used secondary agent, both MMF and azathioprine are limited by delayed onset of action, which often requires weeks to achieve therapeutic effect. This limited their utility in our case of rapidly progressive IRH.<sup><xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R10">10</xref></sup> Calcineurin inhibitors are limited due to the need for careful drug monitoring and their associated nephrotoxicity.</p><p>Tocilizumab is an interleukin-6 antagonist that blocks the T-cell mediated inflammatory cascade, and was used in this case because of emerging evidence that has demonstrated it leads to rapid clinical improvement in severe IRH and other immune-related adverse events.<sup><xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R11">11</xref></sup> We successfully used ruxolitinib as a tertiary agent for IRH after the patient failed to respond to corticosteroids and tocilizumab. The decision to use ruxolitinib was based on past experiences and a review of the existing literature. To our knowledge, there are no other reports describing the use of ruxolitinib for IRH, but it has been successfully used to treat ICI-related myocarditis in case reports.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> Ruxolitinib is a selective Janus kinase (JAK) 1 and JAK2 inhibitor, with a rapid onset of action between days to weeks.<sup><xref ref-type="bibr" rid="R12">12</xref></sup> Ruxolitinib is used for the treatment of myelofibrosis and steroid-refractory graft-versus-host-disease.<sup><xref ref-type="bibr" rid="R13">13</xref></sup> JAK 1 and 2 signaling plays a central role in cytokine-mediated T-cell activation, which is increasingly implicated in the pathogenesis of IRH.<sup><xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R15">15</xref></sup> Recent studies suggest that the pathogenesis of IRH is similar to T-cell mediated graft-versus-host-disease, rather than autoimmune hepatitis which occurs in the absence of immunotherapy and is B-cell driven.<sup><xref ref-type="bibr" rid="R14">14</xref></sup> This highlights why ruxolitinib, and other JAK inhibitors, may be well suited for the treatment of steroid-refractory IRH.<sup><xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R16">16</xref></sup></p><p>Although the corticosteroid dose was escalated at the time of ruxolitinib initiation, the patient had no biochemical improvement after 9 consecutive days of high-dose intravenous corticosteroids, making a delayed response to steroids less likely. While causality cannot be definitively established, the close temporal relationship suggests that ruxolitinib likely contributed to clinical improvement.</p><p>As the use of ICI continues to rise, the incidence of IRH and cases of corticosteroid nonresponse are likely to increase. Further studies are necessary to establish evidence-based guidelines for optimal selection of second-line agents and timing of treatment escalation.</p></sec><sec id="s4"><title>DISCLOSURES</title><p>Author contributions: Writing, original draft: V. Nguyen was responsible for data acquisition and prepared the original draft of the manuscript. A. Montano-Loza assisted in editing the original draft. Writing, reviewing, and editing: V. Nguyen, A. Montano-Loza, M. Wells, C. Moctezuma-Velasquez, M. Anaka, J. Walker, P. Tandon, and R. Bhanji were all involved in reviewing and editing the final manuscript.</p><p>Financial disclosure: None to report.</p><p>Previous presentation: The abstract of this manuscript was presented at the Canadian Digestive Disease Week conference on March 1, 2025, in Quebec City, Quebec, Canada.</p><p>Informed consent was obtained for this case report.</p></sec></body><back><glossary><title>ABBREVIATIONS:</title><def-list><def-item><term id="G1">ALP</term><def><p>Alkaline phosphatase</p></def></def-item><def-item><term id="G2">ALT</term><def><p>Alanine aminotransferase</p></def></def-item><def-item><term id="G3">AST</term><def><p>Aspartate aminotransferase</p></def></def-item><def-item><term id="G4">BID</term><def><p>twice daily dosing</p></def></def-item><def-item><term id="G5">CTCAE</term><def><p>Common terminology criteria for adverse events</p></def></def-item><def-item><term id="G6">ICI</term><def><p>Immune checkpoint inhibitors</p></def></def-item><def-item><term id="G7">IRH</term><def><p>Immune-related hepatitis</p></def></def-item><def-item><term id="G8">IV</term><def><p>Intravenous</p></def></def-item><def-item><term id="G9">MMF</term><def><p>Mycophenolate mofetil</p></def></def-item><def-item><term id="G10">NSCLC</term><def><p>Non-small cell lung cancer</p></def></def-item><def-item><term id="G11">ULN</term><def><p>Upper limit of normal</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Gupta</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Butler</surname><given-names>M</given-names></name></person-group>. <article-title>Checkpoint inhibitor hepatotoxicity: Pathogenesis and management</article-title>. <source>Hepatology.</source>
<year>2024</year>;<volume>79</volume>(<issue>1</issue>):<fpage>198</fpage>–<lpage>212</lpage>.<pub-id pub-id-type="pmid">36633259</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/HEP.0000000000000045</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolte</surname><given-names>FJ</given-names></name>
<name name-style="western"><surname>Hall</surname><given-names>RD</given-names></name>
<name name-style="western"><surname>Shah</surname><given-names>NL</given-names></name></person-group>. <article-title>Immune checkpoint inhibitor-related liver toxicity</article-title>. <source>Clin Liver Dis (Hoboken).</source>
<year>2022</year>;<volume>20</volume>(<issue>3</issue>):<fpage>93</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">36187369</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/cld.1241</pub-id><pub-id pub-id-type="pmcid">PMC9512476</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hercun</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Vincent</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Bilodeau</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Lapierre</surname><given-names>P</given-names></name></person-group>. <article-title>Immune-mediated hepatitis during immune checkpoint inhibitor cancer immunotherapy: Lessons from autoimmune hepatitis and liver immunology</article-title>. <source>Front Immunol.</source>
<year>2022</year>;<volume>13</volume>:<fpage>907591</fpage>.<pub-id pub-id-type="pmid">35844534</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fimmu.2022.907591</pub-id><pub-id pub-id-type="pmcid">PMC9280269</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dougan</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Rubio-Tapia</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Lim</surname><given-names>JK</given-names></name></person-group>. <article-title>AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: Expert review</article-title>. <source>Gastroenterology.</source>
<year>2021</year>;<volume>160</volume>(<issue>4</issue>):<fpage>1384</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">33080231</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1053/j.gastro.2020.08.063</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karim</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Reddy</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Mobin</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Weisberg</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Dinani</surname><given-names>A</given-names></name></person-group>. <article-title>Immunosuppression management for refractory checkpoint inhibitor-related hepatotoxicity</article-title>. <source>Clin Liver Dis (Hoboken).</source>
<year>2024</year>;<volume>23</volume>(<issue>1</issue>):<fpage>e0096</fpage>.<pub-id pub-id-type="pmid">38283303</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/CLD.0000000000000096</pub-id><pub-id pub-id-type="pmcid">PMC10810593</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riveiro-Barciela</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Barreira-Diaz</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Vidal-Gonzalez</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors</article-title>. <source>Liver Int.</source>
<year>2020</year>;<volume>40</volume>(<issue>8</issue>):<fpage>1906</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">32329119</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/liv.14489</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="book"><article-title>Common terminology criteria for adverse events</article-title>. <source>US Department of Health and Human Services</source>, <publisher-name>National Cancer Institute</publisher-name>, <year>2017</year>, Version 5.</mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daetwyler</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Wallrabenstein</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Konig</surname><given-names>D</given-names></name>
<etal/></person-group>. <article-title>Corticosteroid-resistant immune-related adverse events: A systematic review</article-title>. <source>J Immunother Cancer.</source>
<year>2024</year>;<volume>12</volume>(<issue>1</issue>):<fpage>e007409</fpage>.<pub-id pub-id-type="pmid">38233099</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/jitc-2023-007409</pub-id><pub-id pub-id-type="pmcid">PMC10806650</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naidoo</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Murphy</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Atkins</surname><given-names>MB</given-names></name>
<etal/></person-group>. <article-title>Society for immunotherapy of cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology</article-title>. <source>J Immunother Cancer.</source>
<year>2023</year>;<volume>11</volume>(<issue>3</issue>):<fpage>e006398</fpage>.<pub-id pub-id-type="pmid">37001909</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/jitc-2022-006398</pub-id><pub-id pub-id-type="pmcid">PMC10069596</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>SB</given-names></name>
<name name-style="western"><surname>Vembar</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Sukumaran</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Gunawardane</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Hughes</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Smith</surname><given-names>A</given-names></name></person-group>. <article-title>Tocilizumab in grade 4 hepatitis secondary to immune checkpoint inhibitor: A case report and review of the literature</article-title>. <source>Immunotherapy.</source>
<year>2023</year>;<volume>15</volume>(<issue>14</issue>):<fpage>1125</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">37401340</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.2217/imt-2023-0085</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyles</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Farmer</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Abougergi</surname><given-names>M</given-names></name></person-group>. <article-title>A potential new use for tocilizumab: Refractory checkpoint inhibitor hepatitis</article-title>. <source>ACG Case Rep J.</source>
<year>2023</year>;<volume>10</volume>(<issue>9</issue>):<fpage>e01162</fpage>.<pub-id pub-id-type="pmid">37753105</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.14309/crj.0000000000001162</pub-id><pub-id pub-id-type="pmcid">PMC10519460</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Appeldoorn</surname><given-names>TYJ</given-names></name>
<name name-style="western"><surname>Munnink</surname><given-names>THO</given-names></name>
<name name-style="western"><surname>Morsink</surname><given-names>LM</given-names></name>
<name name-style="western"><surname>Hooge</surname><given-names>MNL</given-names></name>
<name name-style="western"><surname>Touw</surname><given-names>DJ</given-names></name></person-group>. <article-title>Pharmacokinetics and pharmacodynamics of ruxolitinib: A review</article-title>. <source>Clin Pharmacokinet.</source>
<year>2023</year>;<volume>62</volume>(<issue>4</issue>):<fpage>559</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">37000342</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s40262-023-01225-7</pub-id><pub-id pub-id-type="pmcid">PMC10064968</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagasia</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Perales</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Schroeder</surname><given-names>MA</given-names></name>
<etal/></person-group>. <article-title>Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): A multicenter, open-label phase 2 trial</article-title>. <source>Blood.</source>
<year>2020</year>;<volume>135</volume>(<issue>20</issue>):<fpage>1739</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">32160294</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1182/blood.2020004823</pub-id><pub-id pub-id-type="pmcid">PMC7229262</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagiwara</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Watanabe</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Kudo</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease</article-title>. <source>Sci Rep.</source>
<year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>9242</fpage>.<pub-id pub-id-type="pmid">33927311</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41598-021-88824-1</pub-id><pub-id pub-id-type="pmcid">PMC8085223</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patil</surname><given-names>PA</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name></person-group>. <article-title>Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy</article-title>. <source>Arch Pathol Lab Med.</source>
<year>2021</year>;<volume>145</volume>(<issue>5</issue>):<fpage>571</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">32338534</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.5858/arpa.2020-0070-RA</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeiser</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Polverelli</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Ram</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease</article-title>. <source>N Engl J Med.</source>
<year>2021</year>;<volume>385</volume>(<issue>3</issue>):<fpage>228</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="pmid">34260836</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1056/NEJMoa2033122</pub-id></mixed-citation></ref></ref-list></back></article>